Verona Emerges Victorious From Second COPD Trial
Ensifentrine Will Head To FDA In First Half Of 2023
After once again showing significant improvements in lung function and a 36% reduction in rate of exacerbations over 24 weeks, Verona is confident that its dual PDE3/4 inhibitor will change the treatment paradigm for COPD.
